Company news
Dianthus Therapeutics, Inc. news in 2020
Dianthus Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145 Phase 1 Results and Update on Targeted ADC Conditioning Program MGTA-117 at ASH Annual Meeting
December 6, 2020
Magenta Therapeutics Appoints Steve Mahoney as Chief Financial and Operating Officer
November 8, 2020
Magenta Therapeutics Reports Recent Business Highlights and Third Quarter Financial Results
November 4, 2020
Magenta Therapeutics Announces Multiple Presentations Across Stem Cell Transplant Portfolio at The American Society of Hematology (ASH) Annual Meeting
November 3, 2020
Magenta Therapeutics Named Co-Recipient of Grant from the National Institutes of Health to Explore Use of Novel Targeted Conditioning Agents with Gene Editing Approaches to Cure HIV
September 1, 2020
Magenta Therapeutics Appoints Lisa M. Olson as Chief Scientific Officer and Kevin B. Johnson as Senior Vice President, Head of Regulatory and Quality; Announces Transition of Jason Ryan, Chief Operating and Financial Officer
September 1, 2020
Magenta Therapeutics Announced It Will Present Clinical and Pre-Clinical Data from Across Immune and Blood System Reset Portfolio at European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting
August 30, 2020
Magenta Therapeutics Reports Recent Business Highlights and Second Quarter Financial Results
August 5, 2020
Magenta Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 29, 2020
Magenta Therapeutics Launches Proposed Public Offering
June 23, 2020
Magenta Therapeutics Announces Pricing of Public Offering
June 23, 2020
Magenta Therapeutics Announces Collaboration with the National Marrow Donor Program/Be The Match to Advance Development of MGTA-145 for First-Line Mobilization of Stem Cells from Healthy Donors and Subsequent Patient Transplant
June 10, 2020
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences
June 7, 2020
Magenta Therapeutics Presents Data at Annual Meeting of American Society of Gene and Cell Therapy Demonstrating Cells Mobilized with MGTA-145 in a Phase I Trial Are Effective in Gene Therapy Settings
May 13, 2020
Magenta Therapeutics Reports Recent Business Highlights and First Quarter Financial Results
May 6, 2020
Magenta Therapeutics to Host Business Update Conference Call
April 29, 2020
Magenta Therapeutics to Present Data from Across Portfolio at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
April 27, 2020
Magenta Therapeutics Names John Davis Jr., M.D., M.P.H, M.S., Head of Research and Development
April 16, 2020
Magenta Therapeutics Provides Business Update
April 15, 2020
Magenta Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
March 2, 2020
Magenta Therapeutics to Participate in Cowen Health Care Conference on Monday, March 2nd in Boston
February 25, 2020
Magenta Therapeutics Completes Dosing in Phase 1 MGTA-145 Trial, Demonstrating Rapid, Single-Day First Line Stem Cell Mobilization and Collection
February 23, 2020
Magenta Therapeutics Announces Updated Phase 2 Data on MGTA-456 Cell Therapy, Demonstrating Continued Durability in Inherited Metabolic Disorders
February 19, 2020
Magenta Therapeutics to Participate in Guggenheim Healthcare Talks Oncology Day on Thursday, February 13th in New York City
February 5, 2020
Magenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones and 2020 Goals
January 12, 2020
Magenta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th in San Francisco
January 5, 2020
Decks in 2020
- Magenta Therapeutics — Investor Presentation (January 2020)
Investor deck · 43 slides · Jan 13, 2020